Charly Jehanno

Charly Jehanno

Auto-generated profile, based on publicly available information

Charly Jehanno

Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2021 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
FZFederica Zilli
Federica Zilli
PRPedro Marques Ramos
Pedro Marques Ramos
PMPriska Auf der Maur
Priska Auf der Maur
CJCharly Jehanno
Charly Jehanno
ASAtul Sethi
Atul Sethi
MBMohamed Bentires‐Alj
Mohamed Bentires‐Alj
Metastasis is the main cause of deaths related to solid cancers. Active transcriptional programmes are known to regulate the metastatic cascade but the molecular determinants of metastatic colonization remain elusive. Using an inducible piggyBac (PB) transposon mutagenesis screen, we have shown that overexpression of the transcription factor nuclear factor IB (NFIB) alone is sufficient to enhance primary mammary tumour growth and lung metastatic colonization. Mechanistically and functionally, NFIB directly increases expression of the oxidoreductase ERO1A , which enhances HIF1α‐VEGFA‐mediated angiogenesis and colonization, the last and fatal step of the metastatic cascade. NFIB is thus clinically relevant: it is preferentially expressed in the poor‐prognostic group of basal‐like breast cancers, and high expression of the NFIB/ERO1A/VEGFA pathway correlates with reduced breast cancer patient survival.

1 June 2023 in The EMBO Journal
Verified
Journal Article
Closed access
JCJoana Pinto Couto
Joana Pinto Couto
MVMilica Vulin
Milica Vulin
CJCharly Jehanno
Charly Jehanno
MCMarie‐May Coissieux
Marie‐May Coissieux
BHBaptiste Hamelin
Baptiste Hamelin
MBMohamed Bentires‐Alj
Mohamed Bentires‐Alj

19 November 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
MMMadhuri Manivannan
Madhuri Manivannan
CJCharly Jehanno
Charly Jehanno
MKMichal Kloc
Michal Kloc
JMJorge Gomez Miragaya
Jorge Gomez Miragaya
MDMaren Diepenbruck
Maren Diepenbruck
MBMohamed Bentires-Alj
Mohamed Bentires-Alj
Estrogen Receptor alpha (ER)-positive, HER2-negative breast cancers are less aggressive than other subtypes and show good patient clinical outcome because they are likely to respond to endocrine therapies. Unfortunately, therapy-resistant metastases may develop and start an inexorable downhill course. ESR1 mutations leading to resistance to endocrine therapy are prevalent in 20–55% of patients with ER+ metastatic breast cancer. Here, we found that glucocorticoid receptor (GR) activation by dexamethasone in ESR1 mutant metastases-bearing mice decreases liver metastases and prolongs survival. Transcriptomic and proteomic profiling revealed that GR activation not only downregulates estrogen response signature but also induces dramatic loss of ER itself. ChIP-Seq analyses show that prolonged dexamethasone treatment almost completely abrogates ER chromatin binding and that GR binds a subset of ER-related genes, including ESR1 . Finally, the GR activity signature predicts a good outcome in patients with ER+ breast cancer. In summary, we show that dexamethasone inhibits ER+ metastatic growth by depleting ER, and hence could be tested for treating patients with ER+ metastatic breast cancer, particularly those suffering from refractory ESR1 mutant metastases.

24 September 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
TFTamara Fernández-Calero
Tamara Fernández-Calero
RMRaphaël Métivier
Raphaël Métivier
FPFrederic Percevault
Frederic Percevault
LCLéa Clusan
Léa Clusan
MBMewen Briend
Mewen Briend
GFGilles Flouriot
Gilles Flouriot